A Pb-212 Generator Using Resistant Substrate and Rn Cold Trapping

描述（由申请人提供）：在临床前动物试验中，靶向Pb-212治疗在接受最高剂量该治疗的组中显示出治愈。将动物研究中最有效的剂量按比例调整到人身上将使人体所需的剂量从50毫微克增加到100毫微克。本应用程序将研究一种方法，该方法将提供一个支持这些要求的发电机系统。拟议的工作将研究一个发生器系统，该系统将捕获短寿命的氡-220，并分离和测试获得的Pb-212/Bi-212。Ra-224和Th-228发射发生器将扩大到几毫毫雷的水平，并随着时间的推移评估其性能，包括Ra-224或Th-228的总体产量和零突破验证。最后，将测试产品Pb-212/Bi-212标记抗黑色素瘤肽段的适用性，以及期望辐射发生器提高的Pb-212比活性。

DESCRIPTION (provided by applicant): Targeted Pb-212 therapy in preclinical animal tests has shown a cure in groups receiving the highest dose of this therapy. Scaling the dose that was most efficacious in animal studies to people would bring the human dose required from 50 to 100 mCi. This application will research an approach that would provide a generator system that would support these requirements. The proposed work will investigate a generator system that would trap the short-lived radon-220 and isolate and test Pb-212/Bi-212 obtained. The Ra-224 and Th-228 emanation generators would be scaled up to the multi-millicurie level and assessment of their performance over time, including overall yield and verification of zero breakthrough of Ra-224 or Th-228. Finally, the suitability of the product Pb-212/Bi-212 to label anti- melanoma peptide moieties and the improved specific activity of Pb-212 expected of an emanation generator will be tested. PUBLIC HEALTH RELEVANCE: A cure for melanoma, a deadly form of skin cancer, has been demonstrated in preclinical animal tests using Pb-212 labeled peptide. As this therapy moves to the clinic the current generator system needs to be improved to accommodate higher dose levels that are anticipated to be administered.